EP0216841A1 - Proteine a activite antigenique et son utilisation pour le diagnostic de la blennorragie - Google Patents

Proteine a activite antigenique et son utilisation pour le diagnostic de la blennorragie

Info

Publication number
EP0216841A1
EP0216841A1 EP86901939A EP86901939A EP0216841A1 EP 0216841 A1 EP0216841 A1 EP 0216841A1 EP 86901939 A EP86901939 A EP 86901939A EP 86901939 A EP86901939 A EP 86901939A EP 0216841 A1 EP0216841 A1 EP 0216841A1
Authority
EP
European Patent Office
Prior art keywords
proteinaceous material
antibodies
gonorrhoea
strain
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86901939A
Other languages
German (de)
English (en)
Inventor
Nicholas John Parsons
Harry Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858506970A external-priority patent/GB8506970D0/en
Application filed by BTG International Ltd, National Research Development Corp UK filed Critical BTG International Ltd
Publication of EP0216841A1 publication Critical patent/EP0216841A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • This invention relates to an antigenically active protein which can be extracted from Neisseria gonorrhoeae, and to its use in a method of diagnosis of clinical gonorrhoea in human patients.
  • the causative agent of gonorrhoea is the bacterium Neisseria gonorrhoeae.
  • the genus Neisseria are diplococci which attach themselves to mucosal cells.
  • Two species, N_. gonorrhoeae and II. meningitidis, the agent of meningococcal meningitis, also known as epidemic cerebrospinal fever, are important pathogens. There are other, non-pathogenic, species of the genus.
  • N.J. Parsons et al. , Journal of General Microbio ⁇ logy 118, 523-527 (1980) have attempted to assess the diversity of immunotypes of strains of N_. gonorrhoeae. In 21 strains assessed there appeared to be at least 8 different immunotypes. A problem in improving the diagnosis of N_. gonorrhoeae is therefore to find an antigen or antibody which is common to most clinically occur ⁇ ring strains.
  • N_. gonorrhoeae bacteria invading the mucosal tissue are rapidly attached by leucocytes which attempt to kill them by phagocytosis.
  • some gonococci survive and grow intra- cellularly within the cells of the phagocytes.
  • Studies have been in progress at the University of Birmingham, England, for some years to identify the determinants responsible for this ability of gonococci to resist killing by phagocytes. At first there was thought to be an association of the degree of pilation (amount of hairlike pile on the bacterial cell surface) with this resistance to killing by phagocytes.
  • Strain BS4 is resistant to killing by human phagocytes. It was obtained from a laboratory strain BS (Kellogg type 2, small colony-forming, pilated) by selecting gonococci thereof which survived and grew within phagocytes, growing colonies of these gonococci, passaging them four times in plastic chambers implanted subcutaneously in guinea pigs and then growing them by minimal culture on agar.
  • BS4 has long been made available by Professor H. Smith, Department of Microbiology,
  • Strain BSSH is susceptible to killing by human phagocytes. It was obtained from the same laboratory strain BS by selecting gonococci thereof which were killed by phagocytes (these being the majority and recognisable from the survivors by an optical characteristic known as single highlight - the survivors gave a double highlight) and growing colonies on agar. Recently, J.G. Cannon et al. , Infection and Immunity 43,
  • the present inventors have isolated a proteinaceous material from the outer membrane vesicles of the phagocyte-resistant strain BS4 and have shown it to react strongly with an antiserum to the phagocyte-resistant organism.
  • the proteinaceous material can be defined as that obtainable from the strain of Neisseria gonorrhoeae BS4 (NCTC 11922), which strain is resistant to being killed by human phagocytes, said proteinaceous material being obtainable by (but not necessarily obtained by) extraction of the outer membrane vesicles (OMV) in 10 g/litre sodium cholate in an aqueous buffer at pH 9.5 and removing undissolved OMV, fractionating the extract and selecting a fraction comprising (consisting of or including) a proteinaceous material having a relative molecular mass of about 20 kDal and which neutralises antiserum to the phagocyte killing-resistant strain BS4 of Neisseria gonorrhoeae.
  • OMV outer membrane vesicles
  • the invention further provides a method of of assay of " human clinical gonorrhoea which comprises (1) incubating a sample, suspected of containing N. gonorrhoea or antibodies to N. gonorrhoea, from a body fluid of a human patient, (a) with the above-defined proteinaceous material or (b) with antibodies to said proteinaceous material, respectively, and (2) detecting whether neutralisation between the proteinaceous material and the antibodies has taken place.
  • an ELISA is used.
  • the invention includes, of course, a kit for use in such a method of diagnosis comprising (a) the proteinaceous material or (b) antibodies thereto as one component, usually insolubilised, and labelled antibodies as a second component.
  • the kit may also include materials for use as a solid phase or in conjunction with the labelling and so forth, i.e. any materials normally present in EIA, fluorescent, or RIA diagnostic kits.
  • a surprising element in the present invention is that the proteinaceous material interacted with sera from many different patients, giving no false readings. This indicates that the 20 kDal protein is an antigen common to many different strains of N_. gonorrhoeae, as distinct from being merely an antigen specific to BS4. This common antigenicity could not have been predicted.
  • Figure 1 is a graph relating material obtained from fractiona- tion of the cholate extract to a measure of the amount of protein thereby obtained.
  • Figure 2 is a photograph of SDS-PAGE in five lanes, on OMV, sodium cholate extract and various fractions of sodium cholate extract. Description of the preferred embodiments
  • the fraction selected comprising proteinaceous material is that hereinafter designated 1b, defined as the fraction which gives a shoulder to the low molecular mass side of the UV absorption peak at 279 nm during continuous fractionation of the cholate extract by gel filtration.
  • Fraction 1b contains proteins of approximately 35 and 60 kDal and lipopolysaccharide as well as the desired 20 kDal product.
  • the 20 kDal product can be further purified by gel filtration and, if necessary, ion-exchange and the invention therefore includes fraction 1b when thus further purified and components of fraction 1b which also show the antiserum neutra ⁇ lising activity.
  • the 20 kDal protein comprises the phagocyte killing-resistant antigen
  • the proteinaceous material or antibodies thereto can be used in any convenient method of assay (detection or measurement) of gonorrhoea diagnosis.
  • Conveniently sandwich assay is used with the proteinaceous material as solid phase antigen, but competitive and inhibition assays are, of course, alternatives. Labelling is . . .
  • Monoclonal antibodies can be raised against the proteinaceous material of the invention by the now well known methods using for example, mice spleen cells to fuse with a myeloma, for example mouse myeloma cells.
  • Hybridomas from II. gonorrhoeae are not novel, but it is believed that hybridomas secreting antibodies to the proteinaceous material of the invention are novel and they form part of the present invention.
  • hybridomas can of course readily be obtained by the usual screening methodology, using the proteinaceous material of the present invention to detect the desired antibodies by for example, Western blotting.
  • a preferred form of assay of the invention is the sandwich assay wherein either the proteinaceous material or antibodies thereto are insolubilised and after incubation with the liquid sample, the product of the interaction is incubated with labelled anti-human immunoglobulin, unbound label is separated from the insoluble material and any labelled insoluble material is detected or measured.
  • the sandwich assay is illustrated schematically below
  • MCA monoclonal antibodies thereto raised in mice
  • Another form of assay is a competitive or displacement assay wherein either (1) the proteinaceous material or (2) antibodies thereto are insolubilised and incubated (a) with the liquid sample and (b) (1) with an insufficiency of labelled antibody or (2) with an insufficiency of labelled proteinaceous material, respectively, the unbound label is separated from the insoluble material and the label is detected or measured.
  • competitive denotes simultaneous incubation of the competing partners, "displacement” that one is reacted before the other, but that the equilibrium between them is displaced by subsequent addition of the other. This type of assay is illustrated schematically below using the same symbols as above:
  • Kits of the invention will usually include all the above- mentioned components except the sample together with appropriate standards.
  • Polyclonal antibodies can of course be substituted for monoclonal antibodies with the usual disadvantages.
  • the 20 kDal proteinaceous material is also useful as a component of a vaccine. It can therefore be formulated, for this purpose, with an adjuvant or carrier for example of aluminium hydroxide, especially "Alhydrogel” (Registered Trade Mark), or aluminium phosphate. A dosage in the range of 5 to 500 micrograms of 20 kDal protein is likely to be employed.
  • Example 1 shows the preparation and properties of the proteinaceous material "Fraction 1b”.
  • Example 2 illustrates its use in diagnosis.
  • Example 3 shows that the monoclonal antibody (H8) of Cannon ejt ⁇ al. , supra is not anti to a determinant of resistance to killing by phagocytes.
  • Example 4 describes further purification of fraction 1b.
  • Example 5 provides further evidence that the 20 kDal protein of the invention comprises the determinant of phagocyte killing- resistance.
  • Example 6 describes the preparation of hybridoma cell lines.
  • EXAMPLE 1 METHODS Extraction of crude outer membrane vesicles (OMV) with sodium cholate
  • OMV were extracted from strain BS4 (agar) (100 ml; 10 bacteria ml ) in 1 M lithium chloride as described previously (Parsons et al. , loc. cit. 1982). Sedimented OMV were resuspended in glycine/NaOH buffer, 0.1 M, pH 9.5 (approximately 20 ml) contain ⁇ ing sodium cholate (1% w/v) and agitated in 50 ml Erlenmeyer flasks with glass beads (3 mm diameter; 2 beads ml ) on an orbital shaker (60 cycles rnin " ) for 1 hour at 37°C. Undissolved OMV were removed by centrifugation (100,000 g, 1 hour, 4 C) and the extract was fractionated immediately. Fractionation of cholate extract
  • strain BS4 agar
  • 20 ml 4.8 M phenol agar
  • the mixture was cooled to 4 C and the bacteria removed by centrifugation (10,000 g, 10 minutes, 4 C) .
  • the top aqueous layer was retained and the middle and lower layers were re-extracted with distilled water, volume equal to the aqueous layer removed.
  • the combined aqueous phases were pooled, centri- fuged (20,000 g, 10 minutes, 4 C) and dialysed against running tap water at room temperature for 2-3 days.
  • the retentate was treated with 3 volumes of ice-cold dry acetone.
  • the LPS precipitate (approxi ⁇ mately 50 mg) was collected by centrifugation (4000 g, 10 minues, room temperature) , redissolved in distilled water at a concentra- tion equivalent to 2 x 10 11 gonococci ml-1 and dialysed against distilled water for 14-15 hours at room temperature.
  • the product was not purified further; it contained some protein and probably small amounts of nucleic acid and peptidoglycan.
  • KDO 2-keto-3-deoxyoctonate
  • protein and carbohydrate Assays for KDO and protein were as described by Parsons et al. , loc. cit. (1982).
  • Carbohydrate was estimated by the anthrone method using glucose as standard. Indirect tests for the determinant of resistance to intracellular killing; pretreatment of strain BS4 (agar) with unabsorbed and absorbed antisera before phagocytosis tests
  • phago- cytosis tests used strain BS4 (agar) pretreated with antiserum absorbed with a single concentration of the fraction containing the putative determinant. This concentration was equivalent to a
  • the number of gonococci per phagocyte (phagocytic index) seen microscopically on stained films on coverslips placed on the flat surface of the Leighton tubes was determined.
  • the number of phagocytes in the deposits from Leighton tubes was determined from their content of DNA (Parsons et_ al_. , loc. cit. 1981).
  • the washed deposits were scraped off with a rubber-tipped glass rod and suspended in 75 ⁇ l 0.1% (w/v) BSA in PBS. Suspensions from three replicate tubes were pooled and 20 ⁇ l removed for an immediate viable count of gonococci (see below).
  • the remaining pooled phagocyte suspen ⁇ sion was treated with 5 M NaOH (50 ⁇ l) for 1 hour at 37°C and then with indole reagent (indole, 0.02% w/v, in 5 M HC1, 250 ⁇ l) for 10 minutes at 100 C. Cooled samples were extracted with chloroform (1 ml) by vortex mixing (30 s) and the absorbance at 490 nm, ,_ n (in a Pye-Unicam SP 1800 spectrophotometer) of the aqueous phase obtained by centrifugation (3000 g, 10 minutes, room temperature) was read against a blank of 0.1% (w/v) BSA in PBS after reaction with the indole reagent.
  • the number of phagocytes on the surface of the Leighton tube (4-20 x 10 in most tests) was obtained from a standard curve relating A, _ to numbers of phagocytes obtained from 12 different donors (Parsons et al. , loc. cit. 1981).
  • the number of viable gonococci in the phagocyte deposits was obtained by plating the 20 ⁇ l sample of the suspension used for DNA assay (see above). The viable counts were corrected for settled non-cell-associated gonococci by deducting the low viable counts ( ⁇ 10% of those in tubes containing phagocytes) found in control tubes without phagocytes. The results (Tables 1 and 2) were expressed as the percentage of the total cell-associated gonococci (the product of the phagocytic index and the total number of phagocytes) that were viable.
  • phagocyte ⁇ g BSA ( ⁇ g glucose (% of total micro-)
  • phagocyte ⁇ g BSA ( ⁇ g glucose (% of total micro ⁇
  • phagocytosis test was described in the text. Suspensions of human phagocytes (10 ; about 80% PMN phagocytes) were mixed with 10 BS4 (agar) organisms (>60% viable) in Leighton tubes and, after incubating (1 hour, 37 C), viable and visual counts of gonococci and counts of total numbers of phagocytes were made as described by Parsons ejt ⁇ al. , loc cit. (1981).
  • fraction 1b was as active as fraction 1a and
  • the LPS preparations contained a protein but far less than was in the cholate extracts.
  • Figure 2 shows the protein patterns on SDS-PAGE for OMV
  • Lane 1 whole cholate (Lane 2) extract and fractions 1a (Lane 3) and 1b (Lane 4) from the "Sephadex G75" column.
  • the materials of Lanes 1-4 were examined in amounts equivalent to the same numbers of gonococci (50 ⁇ l
  • the principal membrane proteins of Neisseria gonorrhoeae were very much reduced in fraction 1b compared with the OMV, cholate extract and fraction 1a, thus indicating they were not associated with phagocyte resistance.
  • proteins A, B and C were much reduced or not detected in the biologically active fraction 1b.
  • the proteins in fraction 1b that appeared to be present in similar amounts in the equally biologically active fraction 1a, and in OMV and the cholate extract, were a group of proteins in the 60 kDal region (marked X in Figure 2) and one or more proteins in a diffuse band around 20 kDal (marked Y in Figure 2) .
  • EXAMPLE 2 This Example illustrates the use of the proteinaceous material of the invention in diagnosis.
  • fraction 1b 0.5 ⁇ g ml protein
  • the optimum amount of fraction 1b (0.5 ⁇ g ml protein) to use as antigen in a survey of patients serum was obtained by reacting logarithmic dilutions of the fraction (10 ⁇ g - 0.001 ⁇ g protein ml- ) against logarithmic dilutions (1/10 - 1/10 ) of hyper-immune rabbit serum against strain BS4 (agar) .
  • the fraction 1b was coated onto the plastic wells of a "Titertek" multiwell plate by a conventional method. 100 micro- litre volumes were used. Human patient serum and sheep anti-human IgG labelled with alkaline phosphatase were added to the wells. After incubation and washing the enzyme activity of the solid phase was measured to determine the extent of neutralisation. In two similar comparisons of sera from 19 gonococcal patients and from 11 persons with no history of gonorrhoea using 0.5 ⁇ g ml (protein) of fraction 1b as antigen, the two types of sera were easily distinguished at 1/10, 1/100 and 1/1000 dilutions.
  • Tests were carried out to establish whether monoclonal antibody to the H8 antigen of Cannon et al. , loc. cit. neutralised resistance of gonococci (strain BS4) to killing by phagocytes.
  • the BS4 gonococci were incubated in tissue culture medium containing the antibody (1 hour, 37 C) before mixing with human phagocytes in the test described in Example 1.
  • the resistance of strain BS4 (agar) to killing by phagocytes was not neutralised at all by the monoclonal antibody even when concen ⁇ trated 8-fold; in contrast antiserum against whole BS4 (agar) organisms greatly reduced the resistance.
  • Fraction 1b prepared as described in Example 1 (8-10 ml: derived from 5 x 10 gonococci ml and containing about 1 mg ml protein) was re-fractionated on a column (1 m x 2.5 mm) of "Sephadex G25" with glycine/NaOH (0.1 M, " pH 9.59) containing sodium cholate 1% (w/v) as eluant. Appropriate fractions were taken from the region where components of 20 kDal would elute.
  • This region was indicated by preliminary calibration of the column with the following marker materials: ribonuclease A, chymotrypsinogen A, ovalbumin, bovine serum albumin and blue dextran 13.7, 15.0, 43.0, 67.1 and 2000 kDal respectively) , under the same conditions as for the gonococcal fraction.
  • the final material was freeze-dried and desalted on a column of "Sephadex G25" (1 m, 15 mm) using water as eluant.
  • the eluate was freeze-dried, dissolved in phosphate-buffered saline pH 7.2 (volume 1/25 of that of the original solution of fraction 1b) and kept at -20 C. It contained between 1 and 1.5 g ml- of protein.
  • This example describes preparation of a hybridoma cell line.
  • Female Balb C mice were injected with the purified 20 kDal protein in physiological saline (approximately 1 mg protein/ml) . Emulsions were made with an equal volume of complete/incomplete
  • CFA/FA Freund's adjuvant
  • mice were test bled for antibody 1 day before fusion.
  • a sandwich ELISA was carried out using immobilised 20 kDal protein, the mouse serum and enzyme labelled rabbit anti-mouse IgG. The test showed that antibodies to the protein had been made by the mouse.
  • Hybridomas were then prepared by fusing spleen cells from the mice with mouse myeloma cells using the procedure described by BRL (UK) Ltd. in the instruction manual supplied with the "Hy BRL Prep.
  • Kit ("Reagents and Instructions for Hybridoma Production", 1982 BRL (UK) Ltd., Cambridge CB4 4BE, England), except that the myeloma cells used were NS-1 instead of NP-3 mentioned in the manual. From 5 microtitre plates of 96 wells per plate 85 wells contained hybridomas which showed by ELISA a reaction to fraction 1b. Of these 9 showed by ELISA a reaction to the 20 kDal protein.
  • Hybridomas obtained by this procedure can be screened against fraction 1b by Western blotting to detect cells which produce antibodies thereto, and the positive cells further tested against the 20 kDal protein itself.

Abstract

Un matériau protéinique ayant une masse moléculaire d'environ 20kDal isolé d'un extrait de cholate de sodium des vésicules de la membrane extérieure d'une souche de Neisseria gonorrhoeae comprend un déterminant de la résistance des N. gonorrhoeae aux attaques mortelles par des phagocytes. Il neutralise l'antisérum de la souche résistante aux phagocytes dont il est isolé, et s'est révélé utile dans des tests de dépistage de blennorragie clinique humaine. Il est également utile comme vaccin.
EP86901939A 1985-03-18 1986-03-13 Proteine a activite antigenique et son utilisation pour le diagnostic de la blennorragie Withdrawn EP0216841A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US789725 1977-04-20
GB858506970A GB8506970D0 (en) 1985-03-18 1985-03-18 Antigenically active protein
US78972585A 1985-10-21 1985-10-21
GB8506970 1985-10-21

Publications (1)

Publication Number Publication Date
EP0216841A1 true EP0216841A1 (fr) 1987-04-08

Family

ID=26288992

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86901939A Withdrawn EP0216841A1 (fr) 1985-03-18 1986-03-13 Proteine a activite antigenique et son utilisation pour le diagnostic de la blennorragie

Country Status (3)

Country Link
EP (1) EP0216841A1 (fr)
GB (1) GB2172704B (fr)
WO (1) WO1986005592A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68925387T2 (de) * 1988-06-22 1996-08-14 Hygeia Sciences Ltd Verfahren zur Behandlung von Immunotest-Proben, die Schleim enthalten
GB8921227D0 (en) * 1989-09-20 1989-11-08 Wellcome Found Antibodies and proteins
WO2009108307A2 (fr) * 2008-02-26 2009-09-03 University Of Massachusetts Utilisation d’anticorps monoclonaux anti-h8 à des fins de diagnostic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178359A (en) * 1976-10-12 1979-12-11 Hoffmann-La Roche Inc. Immunoassay method
NL7804410A (nl) * 1977-05-09 1978-11-13 Merck & Co Inc Werkwijze voor het bepalen van de titer van een anti- lichaam tegen een gramnegatieve bacterie, respectieve- lijk voor het bepalen van de identiteit van een gramne- gatieve bacterie alsmede proefkit voor het uitvoeren van de werkwijze. 250478 werkwijze voor het bepalen van de titer van een anti- lichaam tegen een gramnegatieve bacterie, respectieve- gatieve bacterie alsmede proefkit voor het uitvoeren
GB2018796B (en) * 1978-03-29 1982-07-28 Ici Ltd Emulsifiable compositions
US4220450A (en) * 1978-04-05 1980-09-02 Syva Company Chemically induced fluorescence immunoassay
US4241045A (en) * 1978-05-15 1980-12-23 Research Corporation Purified antigen to test for Neisseria gonorrheae antibodies
US4332890A (en) * 1978-05-15 1982-06-01 Abbott Laboratories Detection of neisseria gonorrhoeae
US4288557A (en) * 1978-10-12 1981-09-08 Merck & Co., Inc. Antigenic complex from N. gonorrhoeae
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
WO1983003354A1 (fr) * 1982-03-30 1983-10-13 Us Army Vaccin anti-neisseria gonorrhoeae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8605592A1 *

Also Published As

Publication number Publication date
WO1986005592A1 (fr) 1986-09-25
GB2172704A (en) 1986-09-24
GB2172704B (en) 1988-07-13
GB8606293D0 (en) 1986-04-16

Similar Documents

Publication Publication Date Title
Rice et al. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum.
Macdonald et al. Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis
Steinmetz et al. Purification and characterization of an exopolysaccharide of Burkholderia (Pseudomonas) pseudomallei
Schneider et al. Instability of expression of lipooligosaccharides and their epitopes in Neisseria gonorrhoeae
US4683196A (en) Method and materials for the identification of lipopolysaccharide producing microorganisms
Goldman et al. Serum-resistant mutants of Escherichia coli O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen
JP2007119468A (ja) 通常のスタフィロコーカス抗原と反応する広い反応性のオプソニン抗体
Whelan et al. Isolation and characterization of cell surface mutants of Candida albicans
Martin et al. Identification of Vibrio vulnificus O serovars with antilipopolysaccharide monoclonal antibody
EP0005512B1 (fr) Méthode sérologique pour la détection d'anticorps de Neisseria gonorrhoeae dans le sérum humain, un antigène spécifique stable à la chaleur, à utiliser dans cette méthode, mode de préparation de cet antigène
Fujita et al. Enzyme-linked immunosorbent assay measurement of fluctuations in antibody titer and antigenemia in cancer patients with and without candidiasis
US7279162B1 (en) Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
Tsang et al. A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide
WO1985002685A1 (fr) Procede et substances permettant l'identification de micro-organismes produisant du lipopolysaccharide
Shinoda et al. Inhibitory effect of capsular antigen of Vibrio vulnificus on bactericidal activity of human serum
EP0216841A1 (fr) Proteine a activite antigenique et son utilisation pour le diagnostic de la blennorragie
Kohno et al. Purification and characterization of Serratia marcescens US5 pili
Godfrey et al. Distribution of porin and lipopolysaccharide antigens on a Pseudomonas aeruginosa permeability mutant
CN111748042B (zh) 一种含有内毒素的非洲猪瘟融合蛋白及其制备方法和应用
EP0761819A1 (fr) Exopolysaccharides du burkholderia pseudomallei et burkholderia mallei
López-Ribot et al. A comparative study on cell wall antigens and cell surface hydrophobicity in clinical isolates of Candida albicans
Reiss et al. Antigenemia in rabbits infected with Candida albicans serotype B: detection by enzyme immunoassay and preliminary characterization of the antigen
EP0918796B1 (fr) Anticorps monoclonal permettant d'agglutiner e. coli possedant une proteine de la famille cs4-cfa/i
EP0783520A1 (fr) Anticorps a activite opsonique etendue reagissant avec les antigenes du staphylocoque
US7094883B1 (en) Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19861104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 19890206

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRITISH TECHNOLOGY GROUP LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19920924

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SMITH, HARRY

Inventor name: PARSONS, NICHOLAS, JOHN